Brief: Ligand Subsidiary Pelthos Therapeutics To Combine With Channel Therapeutics

Ligand Pharmaceuticals Incorporated

17/04/2025 11:06

April 17 (Reuters) - Channel Therapeutics Corp CHRO.A:

LIGAND SUBSIDIARY PELTHOS THERAPEUTICS TO COMBINE WITH CHANNEL THERAPEUTICS

CHANNEL THERAPEUTICS CORP - PROPOSED TRANSACTION WILL RAISE $50 MILLION IN EQUITY CAPITAL

CHANNEL THERAPEUTICS CORP - LIGAND IS ENTITLED TO A 13% ROYALTY ON WORLDWIDE SALES OF ZELSUVMI

CHANNEL THERAPEUTICS CORP -COMBINED CO TO OPERATE UNDER NAME PELTHOS THERAPEUTICS INC., TRADE ON NYSE AMERICAN EXCHANGE UNDER TICKER PTHS

CHANNEL THERAPEUTICS CORP - UPON COMPLETION OF DEAL, PLESHA TO BECOME CEO OF COMBINED CO AND KNUETTEL TO BECOME CFO

Source text: ID:nGNX3XSQny

Further company coverage: CHRO.A

 ((Reuters.Briefs@thomsonreuters.com;))